Voices: Poll of the day: Should weight loss drugs like Mounjaro be widely available on the NHS?
A major expansion of NHS weight loss treatment begins today, as GPs across England are now able to prescribe Mounjaro – an injectable drug also known as tirzepatide – for the first time.
Once limited to specialist clinics or private prescriptions, Mounjaro will now be accessible through general practice for people with severe obesity, specifically, those with a BMI over 40 and at least four related health conditions, such as type 2 diabetes, heart disease, or sleep apnoea.
The move is part of a wider rollout aimed at reaching around 220,000 people over the next three years.
Supporters see it as a breakthrough in tackling obesity-related illness and easing long-term pressure on the NHS. But others, including leading GPs and pharmacy experts, have warned of potential downsides – from increasing workload and training demands to fears the drug will be seen as a quick fix without proper lifestyle support.
'There's no silver bullet,' said Professor Kamila Hawthorne, chair of the Royal College of GPs. 'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later,' she added.
As the NHS begins this major initiative, we want to know what you think: should weight loss drugs like Mounjaro be made widely available on the NHS? Or should they only be reserved for the most severe cases?
Vote in our poll and share your views in the comments below.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
In Pictures: Brighton's Race for Life Pretty Muddy event
Cancer Research UK's annual Race for Life weekend kicked off with a morning of muddy mayhem. Cancer Research UK's Pretty Muddy event in Stanmer Park saw adults and children navigate a mud-splattered obstacle course. Around 1,300 participants clambered, crawled, and bounced their way through a variety of challenges, including a scramble net, tunnels, a mud pit, climbing frames, space hoppers and, for the grand finale, a giant inflatable slide into a bath of thick mud. Today offers a cleaner but no less spirited affair, with options for participants to walk, jog, or run 3k, 5k, or 10k routes.
Yahoo
an hour ago
- Yahoo
Government's new health strategy ‘no more than hiding the crisps', Tories say
The Government's 10-year health strategy to tackle demand on the NHS centres on 'hiding the crisps', a shadow minister has said. Under new proposals, retailers could be made to set targets to increase their sales of less fattening products. Shadow work and pensions secretary Helen Whately said setting mandatory targets for supermarkets was 'nanny state'. 'They had 14 years in opposition to think about what they wanted to do about the NHS, they've had a year in government, and the number one thing in it seems to be hide the crisps,' she told Sky News' Sunday Morning With Trevor Phillips. 'It's obviously the nanny state, but it's also not what people want for the NHS. 'People want to hear how they're going to get to see their GP. 'Telling people what to buy, I think, is not up to government. I believe in personal responsibility.' Health Secretary Wes Streeting told the same programme the Government will work with supermarkets to help 'nudge people in the right direction'. 'By taking the approach we're taking with supermarkets, they will decide through the combination of where they put their products, how they do price promotions, the reformulation, what products they choose to put on the shelves,' he said. 'They will work with us to make sure that we nudge people in the right direction without any of us even noticing, in the same way that we've nudged the country in the other direction since the 1990s.' Rejecting suggestions that the idea was too controlling, he said it was different to 'traditional nanny statism, where we regulate more heavily on price, on marketing, on what's sold'. Labour's 10-year health plan is set to be published next week. Other changes could include money for hospitals being linked to patient ratings. According to the Times, part of the proposals will see patients contacted a few weeks after their hospital treatment for feedback. Based on their responses, money could be diverted to a local 'improvement fund'. Another proposal could see NHS users awarded points for upping their step count and eating healthily. Points can then be traded for vouchers, with discounts at supermarkets and coffee shops, according to The Sun. Hundreds of bodies responsible for overseeing and running parts of the NHS in England are likely to be scrapped as part of the changes. Mr Streeting has said the current system is too complex and needs reform.
Yahoo
an hour ago
- Yahoo
Citi Expresses Optimism for Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that 'compelling' data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a 'dynamic' consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company's (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm's model. It thus believes that Eli Lilly and Company's (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an 'income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.' Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company's strong financials. While we acknowledge the potential of LKQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
